In this report, we describe the establishment and characterisation of a laboratory-based drug screening platform that compares drug responses between multiple hiPSC lines in the pluripotent state. The platform combines a cell painting assay advanced analytics and mass-spectrometry (MS)-based proteomic profiling to detect and explain variable drug responses.